Broker pleads guilty to passing insider info on Gilead's Pharmasset deal; J&J gets private-equity offers for diagnostics biz;

@FiercePharma: It's official: Roche's Perjeta nabs speedy  nod in early breast cancer. Kadcyla next? Story | Follow @FiercePharma

@CarlyHFierce: Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds. ICYMI yesterday | Follow @CarlyHFierce

> A former Morgan Stanley financial adviser pleaded guilty to insider trading after tipping off a friend about Gilead Sciences' ($GILD) plan to buy Pharmasset for $11.2 billion in 2011. Report

> Johnson & Johnson ($JNJ) reportedly received offers from major private equity firms for its Ortho Clinical Diagnostics unit. Report | More from FierceMedicalDevices

> Sanofi ($SNY) CEO Christopher Viehbacher told reporters in Mumbai that he expects global pricing pressures to continue. Report

> Mylan ($MYL) rolled out a generic version of Pfizer's ($PFE) antifungal liquid, Vfend oral suspension. Release

> What's tough for branded drugmakers is good for drugstore profits: Walgreen ($WAG) profits beat estimates on increased use of generic drugs. Report

> Teva Pharmaceutical Industries ($TEVA) launched its generic version of the AbbVie ($ABBV) drug for hyperparathyroidism in kidney patients, Zemplar. Report

> Prescription drug use among U.S. seniors has reached a plateau, and per-capita market growth in this age group is expected to slow. Report

Medical Device News

@FierceMedDev:  | Follow @FierceMedDev

@MarkHFierce: Two U.S. insurers will now cover MDxHealth's prostate cancer Dx test--a major win. It's hard to get coverage. Press release | Follow @MarkHFierce

@MichaelGFierce: MIT nanoparticles help deliver vaccines to mucosal surfaces. More from FierceDrugDelivery | Follow @MichaelGFierce

> PerkinElmer expands MA life sciences research presence. Article

> Report: Blackstone, Bain, other equity firms bid for J&J's Dx unit. More

Biotech News

@FierceBiotech: Most popular story on our website in Sept.: In big setback, GlaxoSmithKline's cancer immunotherapy MAGE-A3 flunks PhIII goal. Story | Follow @FierceBiotech

@JohnCFierce: Pretty clear that Perlmutter now becomes the head wheeler dealer at Merck. Good role for him. Buying and selling. | Follow @JohnCFierce

@DamianFierce: Amid all this talk of axing jobs, have a look at FierceBiotech's rundown of just how much R&D chiefs get paid. Top 15 highest paid biopharma R&D chiefs | Follow @DamianFierce

> Serial NC startup team eyes another deal with latest biotech. More

> Struggling Merck slashing 8,500 jobs in major R&D, commercial reorganization. News

> Geron unloads its stem cell coffers to BioTime in stock deal. Story

> Shutdown looming, FDA approves new depression drug from Lundbeck, Takeda. Article

Biotech Research News

@EmilyMFierce: What happens to the FDA in a government shutdown? ICYMI from FierceBiotech | Follow @EmilyMFierce

> New approach could treat common childhood brain cancer. Report

> Antidepressants could provide new way to treat deadly lung cancer. More

> Antifungal drug abolishes HIV in cells. Article

> New approach could treat common childhood brain cancer. Story

> Evolva in talks with U.S. government for $14.7M antibacterial contract. Item

Pharma Manufacturing News

@EricPFierce: Growing Bayer HealthCare gets new leader. Pfizer exec Olivier Brandicourt takes over top job Nov. 1. ICYMI from FiercePharma | Follow @EricPFierce

> Legislation defines when FDA can take action against compounders. Story

> GSK opens $40M plant in Cork, Ireland, adding 20 jobs. More

> Merck joins Bahrain venture. News

> FDA plant inspections continue, even in government chaos. Item

> Boehringer Ingelheim Shanghai plant tripling capacity. Article

And Finally... Should vaccine makers resurrect the Lyme disease shot that mired GlaxoSmithKline ($GSK) in trouble more than a decade ago? Report (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.